Acute Megakaryoblastic Leukemia (AMKL) Fusion Genes (SJ-01-0001)



Technology Name
(St. Jude Reference #)
Acute Megakaryoblastic Leukemia (AMKL) Fusion Genes (SJ-01-0001)
Description Researchers at St. Jude Children's Research Hospital and the Hospital for Sick Children identified the t(1;22)(p13;q13) translocation whose resulting fusion genes, RBM15 and MKL1, are associated with acute megakaryoblastic leukemia (AMKL).  The nucleotide sequence encoding the RBM-15/MLK fusion protein provides a useful diagnostic assay for identifying this leukemia.  Other aspects of this invention are methods for identifying agents capable of binding to the fusion protein and for identifying agents useful for treating patients with AMKL.
Keywords  Acute Megakaryoblastic Leukemia, AMKL; fusion gene; translocation
Granted Patents or Published Applications U.S. Patent No. 7,329,744
Related Scientific References

Ma et al., “Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia”, Nature Genetics 28(3): 220-221 (2001)

Cen B. Selvaraj, et al.  "Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum  response factor (SRF), is required for serum induction of SRF target genes."  Mol Cell Biol. 2003 Sep:23(18):6597-608.

Licensing Opportunities We are currently seeking licensing opportunities in all fields for the development of this technology. 

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: September 2008